Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Jennison

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
BMJ Open|December 29, 2020
TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocolCatherine Angwin, Caroline Jenkinson, Angus Jones, et al.
Medrxiv : the Preprint Server for Health Sciences|April 24, 2023
Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor AgonistsMahesh M Umapathysivam, Elisa Araldi, Benoit Hastoy, et al.
Diabetes Care|December 16, 2020
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT StudyRoberto Bizzotto, Christopher Jennison, Angus G Jones, et al.
Genome Medicine|March 29, 2026
Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonistsMahesh M Umapathysivam, Elisa Araldi, Benoit Hastoy, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
BMJ Open|December 29, 2020
TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocolCatherine Angwin, Caroline Jenkinson, Angus Jones, et al.
Medrxiv : the Preprint Server for Health Sciences|April 24, 2023
Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor AgonistsMahesh M Umapathysivam, Elisa Araldi, Benoit Hastoy, et al.
Diabetes Care|December 16, 2020
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT StudyRoberto Bizzotto, Christopher Jennison, Angus G Jones, et al.
Genome Medicine|March 29, 2026
Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonistsMahesh M Umapathysivam, Elisa Araldi, Benoit Hastoy, et al.
Pageof 3